FDA Approves Genetic Hearing Loss Therapy Through CNPV Pilot Program

Lunsotogene parvec-cwha (Otarmeni) received FDA approval as the first-ever dual adeno-associated virus (AAV) vector-based gene therapy for the treatment of severe-to-profound and profound sensorineural hearing loss, according to a news release.¹

“Today’s approval is a significant milestone in the treatment of genetic hearing loss,” said FDA Commissioner Marty Makary, MD, MPH, according to the release. “Through the National Priority Voucher pilot program, the agency is accelerating therapies for rare diseases with unmet medical needs while proving we can successfully review even the most complex submissions—such as novel dual-vector gene therapies and combination products requiring coordination across multiple offices and centers—in significantly shortened timeframes.”

This landmark decision, issued just 61 days after the initial filing, represents the fastest approval of its kind in modern history and serves as a major success for the Commissioner’s National Priority Voucher (CNPV) pilot program. For the pharmacy profession, this breakthrough signals a transformative era in sensory medicine, moving beyond sound amplification toward molecular restoration.^1,2

Lunsotogene parvec-cwhais specifically indicated for pediatric and adult patients with severe-to-profound sensorineural hearing loss associated with biallelic variants in the OTOF gene.¹

READ MORE: FDA Approves First-Ever OTC Hearing Aid Software

This specific condition is categorized as an auditory synaptopathy, where the inner ear’s hair cells function normally but fail to transmit sound signals to the auditory nerve due to a lack of the otoferlin protein.^1,3With sensorineural hearing loss accounting for nearly 90% of all hearing loss cases, and traditionally considered permanent, this therapy offers a one-time solution to restore auditory signaling.^2,4

According to the Hearing Health Foundation, the clinical role of the pharmacist is evolving rapidly as these complex biologics enter the market. As the most accessible frontline health care providers, pharmacists are uniquely positioned to bridge the gap in hearing care.⁵

By incorporating hearing health into routine medication therapy management, pharmacists can identify early behavioral signs of hearing loss, such as a patient’s reliance on lip-reading or frequent requests for repetition during counseling.^5,6 Early identification is particularly critical for OTOF-related loss, where delayed diagnosis can miss vital treatment windows and lead to lasting speech delays.^1,3

Beyond screening, pharmacists must navigate the highly technical nature of inner ear drug delivery. Lunsotogene parvec-cwha is a biologic-device combination product administered surgically into the cochlea via a specialized catheter and infusion pump.^1,4

This invasive approach is necessary because the inner ear is protected by the blood-labyrinth barrier, which prevents most systemic medications from reaching the delicate sensory tissues of the cochlea. Understanding these delivery challenges allows pharmacists to better counsel patients on why traditional oral pharmacotherapy has been largely limited to managing acute episodes with corticosteroids rather than providing a cure, according to authors of a Frontiers in Neuroscience study.⁴

Furthermore, the pharmacist’s expertise in ototoxicity remains a cornerstone of preventative care. Many common medications—including specific aminoglycoside antibiotics and antineoplastic agents like cisplatin—are known to damage the hair cells of the inner ear.^2,4,6

By monitoring drug regimens and advocating for baseline hearing tests before and during the use of these ototoxic agents, pharmacists can prevent the very type of permanent sensorineural damage that gene therapies now aim to treat.^2,6

As the FDA prepares for public meetings to discuss the future of the National Priority Voucher program, the medical community is looking toward a future where genetic hearing loss is no longer an insurmountable disability.¹ The approval of lunsotogene parvec-cwha underscores the importance of interprofessional collaboration between pharmacists, audiologists, and otolaryngologists.^3,5

By providing patient-centered education, monitoring for ototoxicity, and facilitating referrals for genetic screening, pharmacists will play a vital role in ensuring that these groundbreaking therapies reach the patients who need them most.⁶

“The FDA granted accelerated approval of Otarmeni to Regeneron Pharmaceuticals, Inc,” concluded authors of the FDA news release.¹ “Continued approval may be contingent upon assessment of durability of hearing improvement along with verification of treatment effects on clinical measures of speech development and quality of life.”

READ MORE: FDA Updates Resource Center

Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our free Drug Topics newsletter.

REFERENCES

1. FDA approves first-ever gene therapy for treatment of genetic hearing loss under National Priority Voucher program. FDA. April 23, 2026. Accessed April 27, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucher

2. Sensorineural hearing loss. Cleveland Clinic. November 15, 2024. Accessed April 27, 2026. https://my.clevelandclinic.org/health/diseases/sensorineural-hearing-loss

3. Azaiez H, Thorpe RK, Odell AM, et al. OTOF-related hearing loss. 2008 Feb 29 [Updated 2025 Mar 13]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1251/

4. Liu SS, Yang R. Inner ear drug delivery for sensorineural hearing loss: current challenges and opportunities. Front Neurosci. 2022 May 24;16:867453. doi: 10.3389/fnins.2022.867453.

5. Hertzano R. How pharmacists can help bridge the gap in hearing care for seniors. Hearing Health Foundation. July 28, 2022. Accessed April 27, 2026. https://hearinghealthfoundation.org/blogs/how-pharmacists-can-help-bridge-the-gap-in-hearing-care-for-seniors

6. David KB. Pharmaceutical care approach to hearing loss. J Health Rep Technol. 2020;6(2):e103340. https://doi.org/10.5812/ijhls.103340